Zastaprazan

Zastaprazan
Clinical data
Trade names	Jaqbo
Other names	JP-1366
ATC code	A02BC12 (WHO) ;
Legal status
Legal status	KR: Rx-only;
Identifiers
	IUPAC name azetidin-1-yl-[8-[(2,6-dimethylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]methanone;
CAS Number	2133852-18-1;
PubChem CID	138622158;
ChemSpider	115007138;
UNII	W9S9KZX5MD;
KEGG	D13240;
Chemical and physical data
Formula	C22H26N4O
Molar mass	362.477 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4;
	InChI InChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3; Key:FEQFUBYYZYQTOJ-UHFFFAOYSA-N;

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker.^[1]^[2] In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD).^[3] In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.^[4]

Other namesJP-1366

Quick facts Clinical data, Trade names ...

Close

References